Model Number 610-0001 |
Device Problems
Improper or Incorrect Procedure or Method (2017); Device Dislodged or Dislocated (2923)
|
Patient Problems
Corneal Clouding/Hazing (1878); Inflammation (1932); Keratitis (1944); Blurred Vision (2137); Visual Impairment (2138); Loss of Vision (2139)
|
Event Date 12/01/2016 |
Event Type
Injury
|
Manufacturer Narrative
|
The explanted device is expected to be returned to the manufacturer.The device history record (dhr) for this manufacturing lot was reviewed and the device met all release criteria and there were no discrepancies or unusual findings that relate to the reported event.Inlay decentration is listed in the device labeling as a known complication of corneal inlay surgery.Dlk is also listed in the device labeling and is commonly associated with corneal flap procedures.The off-label use of celluvisc may have been contributory.Complaint reference number: (b)(4).Date emdr submitted to fda: 12/21/2016.
|
|
Event Description
|
Corneal inlay implantation was performed on (b)(6) 2016 on the left eye.At the one-day postoperative visit, the patient presented with blurred vision and inflammation in the operative eye and diffuse lamellar keratitis (dlk), grade 2, was diagnosed.Steroid administration was increased to hourly.The patient's preoperative best corrected distance visual acuity (bcdva) was 20/20.During investigation of the reported issue, it was discovered that at the end of the procedure several drops of celluvisc had been instilled on the corneal flap.New information was received on november 23, 2015 indicating that the inlay will be explanted.Additional information was requested and on december 15, 2016 the surgeon provided the following update.Initially, the patient's postoperative bcdva decreased from 20/20 to 20/100, but improved to 20/40 on (b)(6) 2016.Prior to inlay explantation the inlay was clear and dlk had decreased to grade 1, but the inlay had decentered nasally.On (b)(6) 2016, the flap was lifted and irrigated and the inlay was removed and replaced with a new inlay in order to address decentering (and dlk).
|
|
Manufacturer Narrative
|
The explanted inlay was returned to the manufacturer and subjected to visual microscopic inspection.The findings revealed that the inlay was folded and dehydrated.As a result no dimensional measurements could be performed.Complaint reference# (b)(4).Date esmdr submitted: 03/02/2017.
|
|
Event Description
|
Two weeks post inlay exchange, the patient's best corrected distance visual acuity (bcdva) remained unchanged at 20/40.On (b)(6) 2017, bcdva improved to 20/30.There is residual mild corneal haze observed just outside the area of inlay.Steroid treatment is being tapered.
|
|
Manufacturer Narrative
|
Correction for 3005956347-2016-00011-001: [correct information for received by mfr date is 02/01/2017 and not 01/27/2017].(b)(4).
|
|
Event Description
|
Patient's current status was requested and the following update was provided on august 1, 2017: the patient was last examined on (b)(6) 2017, the patient's best corrected visual acuity (bcdva) was 20/40 and the patient was directed to continue artificial tears.
|
|
Search Alerts/Recalls
|